Appointment of David Lescuyer as EVP Oral Business
OREANDA-NEWS. Skyepharma PLC (LSE SKP), the expert oral and inhalation drug development company, today announces that David Lescuyer has been appointed as Executive Vice President, Oral Business, reporting to Peter Grant, CEO, and joined the Group on 11 April 2016.
David will be responsible for Skyepharma's Oral Business including, once the lease with Aenova has expired on 30 June 2016, the manufacturing operations in Saint-Quentin Fallavier, near Lyon, France ("Lyon Business").
Over the coming weeks, David will be meeting Oral Business customers as well as familiarising himself with the Lyon Business ahead of its return to Skyepharma. With immediate effect, Guy Vergnault, Vice President, Oral Drug Delivery Solutions, will report to David.
David, a French national, joins from Patheon Pharmaceuticals where he was Executive Director and General Manager, Patheon France and more recently Global VP, Operational Excellence. Prior to Patheon, David's career included experience with Fareva, Cenexi and Catalent in senior operational and general management roles.
Peter Grant, Chief Executive Officer of Skyepharma, commented:
"We are very pleased that David has joined us and are sure that he will provide excellent leadership at this exciting time for the Oral Business, especially as the Lyon Business returns to Skyepharma in July. David has an excellent track record of improving financial and operating performance in pharmaceutical businesses and the skills to lead further development of the Group's Oral Business."